+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Controlled Release Drug Delivery Market, Drug Dosage, Price and Clinical Pipeline Insight 2029

  • PDF Icon

    Drug Pipelines

  • 900 Pages
  • September 2023
  • Region: Global
  • Kuick Research
  • ID: 5875319
UP TO OFF until Jul 31st 2024

Report Findings:

  • Global Controlled Release Drugs Delivery Market Opportunity: >.USD 100 Billion By 2029
  • Insight On Drugs Commercially Available In Market: > 150 Drugs
  • Global Controlled Release Drug Clinical Trials Insight: > 230 Drugs
  • Controlled Release Drug Clinical Trials Insight By Company, Country , Indication and Phase
  • Drug Dosage, Patent, Pricing and Sales Insight By Indication
  • Global Controlled Release Drug Regional Market Trends: USA, Europe, Japan, China Canada and South Korea
  • Insight On Key 30 Companies

The concept of controlled release formulations in the pharmaceutical market is a rapidly emerging trend, attracting significant investments from key market players. To combat generic competition, pharmaceutical companies are actively developing sustained release and controlled release versions of their popular drugs, thereby driving the market forward. The administration of controlled release drugs offers several advantages, including reduced dosage and frequency, minimized fluctuations in drug levels, enhanced efficacy, improved patient adherence, and consistent therapeutic effects. By utilizing controlled release drug delivery systems, drugs can be released at specific target sites at predetermined intervals, resulting in predictable release kinetics and prolonged therapeutic benefits compared to conventional administration methods. As a result of these additional advantages, the use of controlled release delivery systems is expected to experience significant growth in the forecast period.

Traditional immediate release formulations often fail to provide the desired pharmacokinetic profiles required for optimal treatment. However, the advent of controlled release drug delivery systems has revolutionized the way medications are administered. These innovative approaches offer numerous advantages, including sustained drug release, targeted delivery, and improved patient compliance. In this article, we delve into the world of controlled release drug delivery and explore its significant impact on patient care. One of the key benefits of controlled release drug delivery systems is their ability to improve drug efficacy. By maintaining sustained therapeutic drug levels, these systems ensure a consistent and prolonged action of the medication. This is particularly crucial for the treatment of chronic conditions or diseases that require continuous drug exposure. Controlled release systems can help achieve therapeutic concentrations over extended periods, effectively managing symptoms, and improving long-term outcomes.

Many medications display a narrow therapeutic window, meaning that the optimal dose lies between a ranges where efficacy is achieved without causing excessive side effects. Immediate-release formulations can lead to rapid drug absorption, resulting in high peak concentrations that may contribute to adverse reactions. Controlled release systems, on the other hand, offer a more controlled and gradual release of the drug, minimizing peak concentrations and reducing the risk of side effects. By providing a more stable drug concentration, these systems contribute to a better tolerability profile, ensuring patient safety and comfort.

Keeping to prescribed medication regimens is a crucial factor in achieving successful treatment outcomes. However, the need for frequent dosing can often pose challenges for patients, leading to non-compliance. Controlled release drug delivery systems address this issue by reducing the dosing frequency. Patients can benefit from prolonged drug action, resulting in fewer administrations and enhanced convenience. This improved compliance not only simplifies treatment regimens but also enhances patient satisfaction and overall treatment success. In many disease conditions, it is desirable to deliver drugs specifically to the affected tissues or cells, while minimizing exposure to healthy tissues. Controlled release drug delivery systems enable targeted drug delivery by employing various strategies. Nanoparticles, liposomes, and other carrier systems can be engineered to specifically accumulate in the desired site, such as tumor tissues in cancer therapy. This targeted approach enhances drug efficacy while reducing off-target effects, ultimately leading to improved therapeutic outcomes.

The field of controlled release drug delivery continues to evolve, with ongoing advancements in technology and research. Scientists are exploring novel materials, such as stimuli-responsive polymers, that can release drugs in response to specific triggers within the body. Additionally, the integration of smart sensors and monitoring devices in these systems holds the potential for personalized medicine, enabling real-time feedback and adaptive drug release. These innovations have the potential to revolutionize disease management and bring about a new era of precision medicine.

Controlled release drug delivery systems have revolutionized patient care by providing sustained and targeted drug delivery, optimizing treatment outcomes, and improving quality of life. From enhancing drug efficacy to reducing side effects and improving patient compliance, these systems have significantly advanced the field of pharmacotherapy. As researchers continue to push the boundaries of innovation, we can anticipate further breakthroughs that will shape the future of controlled release drug delivery, bringing us closer to personalized, effective, and safer therapeutic interventions for a wide range of medical conditions.

Table of Contents

1. Introduction to Controlled Drug Delivery
1.1 Fundamentals & Technology Of Controlled Drug Delivery Systems
1.2 Controlled Drug Delivery Classification: By System, Route & Technology
1.3 Controlled Drug Delivery Mechanism of Action

2. Material Based Approaches for Controlled Drug Delivery
2.1 Polymers
2.2 Chronopharmaceutics
2.3 Nanoparticulate Delivery System

3. Global Controlled Release Drug Delivery Market Trends
3.1 Current Market Scenario
3.2 Future Market Outlook

4. Global Controlled Release Drug Regional Market Trends
4.1 US
4.2 Europe
4.3 Japan
4.4 China
4.5 Canada
4.6 South Korea

5. Global Controlled Release Drugs Clinical Pipeline Overview
5.1 Company
5.2 Country
5.3 Drug Class
5.4 Indication
5.5 Patient Segment
5.6 Phase

6. Controlled Drug Delivery Research & Clinical Trends by Indication
6.1 Diabetes
6.2 Cancer
6.3 Cardiovascular Diseases
6.4 Neurological Disorders
6.5 Infections

7. Global Controlled Release Drugs Clinical Pipeline By Company, Indication & Phase
7.1 Research
7.2 Preclinical
7.3 Phase-I
7.4 Phase-I/II
7.5 Phase-II
7.6 Phase-II/III
7.7 Phase-III
7.8 Preregistration
7.9 Registered

8. Marketed Controlled Release Drugs Clinical Insight
9. Controlled Release Drugs for Alzheimer’s Disease - Pricing, Patent & Dosage Insight
9.1 Namzaric (Extended-Release)
9.2 Namenda XR (Extended-Release)
9.3 Razadyne ER (Extended-Release)

10. Controlled Release Drugs for Parkinson’s Disease - Pricing, Patent & Dosage Insight
10.1 Gocovri (Extended-Release)
10.2 Osmolex ER (Extended-Release)
10.3 Mirapex ER (Extended-Release)

11. Controlled Release Drugs for Schizophrenia - Pricing, Patent & Dosage Insight
11.1 Perseris (Extended-Release)
11.2 Invega (Extended-Release)
11.3 Invega Sustenna/Invega Trinza/Invega Hafyera (Extended-Release)
11.4 Seroquel XR (Extended-Release)
11.5 Abilify Maintena/ Abilify Asimtufii (Extended-Release)
11.6 Aristada/Aristada Initio (Extended-Release)
11.7 Rykindo (Extended-Release)
11.8 Uzedy (Extended-Release)

12. Controlled Release Drugs for Chronic Pain - Pricing, Patent & Dosage Insight
12.1 Hysingla ER (Extended-Release)
12.2 Nucynta ER (Extended-Release)
12.3 Kadian (Extended-Release)
12.4 Xtampza ER (Extended-Release)
12.5 MS Contin (Extended-Release)
12.6 Embeda (Extended-Release)

13. Controlled Release Drugs for Multiple Sclerosis - Pricing, Patent & Dosage Insight
13.1 Ampyra/Fampyra (Extended-Release)
13.2 Tecfidera (Delayed-Release)
13.3 Rayos (Delayed-Release)
13.4 Vumerity (Delayed-Release)
13.5 Bafiertam (Delayed-Release)

14. Controlled Release Drugs for Diabetes Mellitus Type II - Pricing, Patent & Dosage Insight
14.1 Glumetza (Extended-Release)
14.2 Glucotrol XL (Extended-Release)
14.3 Glucophage XR (Extended-Release)
14.4 Bydureon (Extended-Release)
14.5 Trijardy XR (Extended-Release)

15. Controlled Release Drugs for Hypertension & Angina Pectoris - Pricing, Patent & Dosage Insight
15.1 Procardia XL (Extended-Release)
15.2 Toprol XL (Extended-Release)
15.3 Adalat CC (Extended-Release)
15.4 Verelan PM (Extended-Release)
15.5 Cardizem LA (Extended-Release)

16. Controlled Release Drugs for Post-Operative Pain - Pricing, Patent & Dosage Insight
16.1 Zynrelef (Extended-Release)
16.2 Posimir (Sustained - Release)

17. Controlled Release Drugs for HIV - Pricing, Patent & Dosage Insight
17.1 Apretude extended-release
17.2 Cabenuva extended-release
17.3 Rukobia (Extended-Release)

18. Controlled Release Drugs for Attention Deficit Hyperactivity Disorder - Pricing, Patent & Dosage Insight
18.1 Qelbree (extended-release)
18.2 Jornay PM (Extended-Release)
18.3 Cotempla XR-ODT (Extended-Release)
18.4 Adzenys ER (Extended-Release)

19. Controlled Release Drugs for Inflammatory & Autoimmune Diseases - Pricing, Patent & Dosage Insight
19.1 Rinvoq (Extended-Release)
19.2 Ortikos (Extended-Release)
19.3 Xeljanz XR (Extended-Release)

20. Controlled Release Drugs for Bacterial Infections - Pricing, Patent & Dosage Insight
20.1 Aemcolo (Delayed-Release)
20.2 Talicia (Delayed-Release)

21. Controlled Release Drugs for Opioid Use Disorder - Pricing, Patent & Dosage Insight
21.1 Sublocade (Sustained-Release)
21.2 Brixadi (Extended-Release)

22. Controlled Release Drugs for Preventing Organ Transplant Rejection - Pricing, Patent & Dosage Insight
22.1 Astagraf XL (Extended-Release)
22.2 Envarsus XR (Extended-Release)

23. Global Controlled Drug Delivery Market Dynamics
23.1 Market Drivers
23.2 Market Restraints

24. Competitive Landscape
24.1 AbbVie
24.2 Antlia Bioscience
24.3 Arbor Pharmaceuticals (Azurity Pharmaceuticals)
24.4 AstraZeneca
24.5 Bausch Health Companies
24.6 Biodexa Pharmaceuticals
24.7 Camurus
24.8 DURECT Corporation
24.9 Emplicure
24.10 Endo International
24.11 HLK Pharmacin
24.12 Jemincare
24.13 Johnson & Johnson
24.14 Luye Pharma Group
24.15 Lyndra
24.16 Mallinckrodt plc
24.17 MedinCell S.A.
24.18 Merck
24.19 Otsuka Pharmaceutical
24.20 Pacira BioSciences
24.21 Pfizer
24.22 Purdue Pharma
24.23 Roche
24.24 Sanofi
24.25 Serina Therapeutics
24.26 Sun Pharmaceutical Industries
24.27 Supernus Pharmaceuticals
24.28 Takeda
24.29 Tris Pharma
24.30 ViiV Healthcare

List of Figures
Figure 1-1: Limitations of Conventional Drug Delivery Systems
Figure 1-2: Diversification of Novel Drug Delivery Platforms
Figure 1-3: History of Drug Delivery Technology from First Generation till Third Generation
Figure 1-4: Barriers to be Overcome by Third Generation Drug Delivery System
Figure 1-5: Demonstration of Targeted and Non-Targeted Drug Delivery
Figure 1-6: Controlled Drug Release by Zero Order Mechanism
Figure 1-7: Plasma Concentration v/s Time Profile in Conventional and Controlled Release
Figure 1-8: Comparison of Various Modified Drug Release Systems
Figure 1-9: Illustration of Mechanism of Pulsatile Drug Release in Pulsincap
Figure 1-10: Classification Based On Technicality Erudition
Figure 1-11: Structural Differentiation among Different Classified Drug Delivery Systems
Figure 1-12: Classification Based on Route of Administration
Figure 1-13: Differentiation of the Two Diffusion Controlled Mechanisms
Figure 1-14: Mechanism of Encapsulation Dissolution Controlled System
Figure 1-15: Osmotic Release of Drug with Controlled Mechanism
Figure 1-16: Illustration of Erosion Mechanisms Found in Matrix Systems
Figure 2-1: Categorization of Polymeric Controlled Drug Delivery Devices
Figure 2-2: Various Nanostructures Available for Nanoparticulate Delivery System
Figure 3-1: Global - Controlled Release Drug Delivery Market Size (US$ Billion), 2019 - 2022
Figure 3-2: Global - Controlled Release Drug Delivery Market Forecast (US$ Billion), 2023 - 2029
Figure 4-1: US -Controlled Release Market Size (US$ Billion), 2019 - 2029
Figure 4-2: US - Population Above and Below 65 Years of Age (%), 2022
Figure 4-3: Europe -Controlled Release Drug Delivery Market Size (US$ Billion), 2019 - 2029
Figure 4-4: EU - Population Above and Below 65 Years (%), 2022
Figure 4-5: Japan - Population Above and Below 65 Years (%), 2022
Figure 4-6: China - Population Above and Below 65 Years (%), 2022
Figure 5-1: Global - Controlled Release Drug Clinical Pipeline by Company (Number), 2023 Till 2029
Figure 5-2: Global - Controlled Release Drug Clinical Pipeline by Country (Number), 2023 Till 2029
Figure 5-3: Global - Controlled Release Drug Clinical Pipeline by Drug Class (Number), 2023 Till 2029
Figure 5-4: Global - Controlled Release Drug Clinical Pipeline by indication (Number), 2023 Till 2029
Figure 5-5: Global - Controlled Release Drug Clinical Pipeline by Patient Segment (Number), 2023 Till 2029
Figure 5-6: Global - Controlled Release Drug Clinical Pipeline by Phase (Number), 2023 Till 2029
Figure 6-1: Major Non-Invasive Administrative Routes of Insulin Delivery
Figure 6-2: Controlled Drug Delivery Approaches in Cancer Therapeutics
Figure 6-3: Controlled Drug Delivery Approaches used to Deliver Drugs to CNS
Figure 9-1: Namzaric - Price of Oral Capsule, Extended Release of Different Dosages (US$), September’2023
Figure 9-2: Namenda XR - Available Dosage Strengths (mg)
Figure 9-3: Namenda XR - Price of 30 Oral Capsules, Extended Release of Dosages (US$), September’2023
Figure 9-4: Namenda XR - Price of 90 Extended-Release Oral Capsules of Dosage 14 mg, 28 mg (US$), September’2023
Figure 9-5: Razadyne ER - Available Dosage Strengths (mg)
Figure 9-6: Razadyne ER - Price of Oral Capsule, Extended Release of Dosage 8 mg, 16 mg, 24 mg (US$), September’2023
Figure 10-1: Gocovri XR - Available Dosage Strengths (mg)
Figure 10-2: Gocovri - Price of Extended Release Oral Capsules of Dosage 68.5 mg and 137 mg (US$), September’2023
Figure 10-3: Global - Gocovri Annual Sales (US$ Million), 2022-2023
Figure 10-4: Global - Gocovri Quarterly Sales (US$ Million), H1’2023
Figure 10-5: Global - Gocovri Quarterly Sales (US$ Million), 2022
Figure 10-6: Osmolex ER - Available Dosage Strengths (mg)
Figure 10-7: Osmolex ER - Price of Oral Capsule, Extended Release (US$), September’2023
Figure 10-8: Mirapex ER - Available Dosage Strengths (mg)
Figure 10-9: Mirapex ER - Price of Oral Tablet, Extended Release (US$), September’2023
Figure 11-1: Perseris: Available Dosage Strengths (mg)
Figure 11-2: Perseris - Price of Subcutaneous Powder for Injection, Extended Release (US$) September’2023
Figure 11-3: Global - Perseris Annual Sales (US$ Millions), 2019-2022
Figure 11-4: Global - Perseris Quarterly Sales (US$ Millions), H1’2023
Figure 11-5: Global - Perseris Quarterly Sales (US$ Millions), 2022
Figure 11-6: Invega - Available Dosage Strengths (mg)
Figure 11-7: Invega - Price of Oral Tablets, Extended Release of Dosage 1.5 mg, 3 mg and 6mg (US$), September’2023
Figure 11-8: Invega - Price of Oral Tablets, Extended Release of Dosage 9 mg (US$), September’2023
Figure 11-9: Invega Sustenna - Price of Extended Release Intramuscular Suspensions of Different Doses (US$), September’2023
Figure 11-10: Invega Trinza - Price of Extended Release Intramuscular Suspensions of Different Doses (US$), September’2023
Figure 11-11: Invega Hafyera - Price of Extended Release Intramuscular Suspensions of Different Doses (US$), September’2023
Figure 11-12: Global - Invega Sustenna/Invega Trinza Annual Sales (US$ Million), 2019-2023*
Figure 11-13: US - Invega Sustenna/Invega Trinza Annual Sales (US$ Million), 2019-2023*
Figure 11-14: ROW - Invega Sustenna/Invega Trinza Annual Sales (US$ Million), 2019-2023*
Figure 11-15: Global - Invega Sustenna/ Invega Trinza Quarterly Sales (US$ Million), H1’2023
Figure 11-16: US - Invega Sustenna/ Invega Trinza Quarterly Sales (US$ Million), H1’2023
Figure 11-17: ROW - Invega Sustenna/ Invega Trinza Quarterly Sales (US$ Million), H1’2023
Figure 11-18: Global - Invega Sustenna/ Invega Trinza Quarterly Sales (US$ Million), 2022
Figure 11-19: US - Invega Sustenna/ Invega Trinza Quarterly Sales (US$ Million), 2022
Figure 11-20: ROW - Invega Sustenna/ Invega Trinza Quarterly Sales (US$ Million), 2022
Figure 11-21: Seroquel XR - Available Dosage Strengths (mg)
Figure 11-22: Seroquel XR - Prices of Oral Tablets, Extended Release of Different Doses (US$), September’2023
Figure 11-23: Global - Seroquel XR Total Annual Sales (US$ Million), 2019 - 2021
Figure 11-24: Abilify Maintena - Available Dosage Strengths (mg)
Figure 11-25: Abilify Maintena - Price of Intramuscular Powder for Injection, Extended Release (US$), September’2023
Figure 11-26: Abilify Asimtufii - Price of Intramuscular Powder for Injection, Extended Release (US$), September’2023
Figure 11-27: Global - Abilify Maintena Annual Sales (US$ Million), 2019-2021
Figure 11-28: Global - Abilify Maintena Quarterly Sales (US$ Million), H1’2023
Figure 11-29: Global - Abilify Maintena Quarterly Sales (US$ Million), 2022
Figure 11-30: Aristada - Available Dosage Strengths (mg)
Figure 11-31: Aristada - Price of Intramuscular Suspension, Extended Release of Different Doses (US$), September’2023
Figure 11-32: Aristada Initio - Price of Intramuscular Suspension, Extended Release of Dose 675 mg/2.4 mL (US$), September’2023
Figure 11-33: Global - Aristada Annual Sales (US$ Million), 2019-2023*
Figure 11-34: Global - Aristada Quarterly Sales (US$ Million), H1’2023
Figure 11-35: Global - Aristada Quarterly Sales (US$ Million), 2022
Figure 11-36: Rykindo - Available Dosage Strengths (mg)
Figure 11-37: Uzedy - Available Dosage Strengths (mg)
Figure 11-38: Uzedy - Prices of Oral Tablets, Extended Release of Different Doses (US$), September’2023
Figure 12-1: Hysingla ER - Available Dosage Strengths (mg)
Figure 12-2: Hysingla ER - Price of Oral Tablet, Extended Release of Different Doses (US$), September’2023
Figure 12-3: Nucynta ER - Available Dosage Strengths (mg)
Figure 12-4: Nucynta ER - Price of Oral Tablets, Extended Release of Different Doses (US$), September’2023
Figure 12-5: Global - Nucynta ER Annual Sales (US$ Million), 2019-2023*
Figure 12-6: Global - Nucynta ER Quarterly Sales (US$ Million), H1’2023
Figure 12-7: Global - Nucynta ER Quarterly Sales (US$ Million), 2022
Figure 12-8: Kadian - Available Dosage Strengths (mg)
Figure 12-9: Kadian - Price of Oral Capsules, Extended Release of Dosage 10 mg/12 hr (US$), September’2023
Figure 12-10: Kadian - Price of Oral Capsules, Extended Release of Dosage 10 mg/12 to 24 hr and 10 mg/24 hr (US$), September’2023
Figure 12-11: Kadian - Price of Oral Capsules, Extended Release of Dosage 20 mg/12 hr (US$), September’2023
Figure 12-12: Kadian - Price of Oral Capsules, Extended Release of Dosage 20 mg/12 to 24 hr and 20 mg/24 hr (US$), September’2023
Figure 12-13: Kadian - Price of Oral Capsules, Extended Release of Dosage 30 mg/12 hr (US$), September’2023
Figure 12-14: Kadian - Price of Oral Capsules, Extended Release of Dosage 30 mg/12 to 24 hr and 30 mg/24 hr (US$), September’2023
Figure 12-15: Kadian - Price of Oral Capsules, Extended Release of Dosage 40 mg/12 to 24 hr and 40 mg/24 hr (US$), September’2023
Figure 12-16: Kadian - Price of Oral Capsules, Extended Release of Dosage 50 mg/12 hr (US$), September’2023
Figure 12-17: Kadian - Price of Oral Capsules, Extended Release of Dosage 50 mg/12 to 24 hr and 50 mg/24 hr (US$), September’2023
Figure 12-18: Kadian - Price of Oral Capsules, Extended Release of Dosage 60 mg/12 hr (US$), September’2023
Figure 12-19: Kadian - Price of Oral Capsules, Extended Release of Dosage 60 mg/12 to 24 hr (US$), September’2023
Figure 12-20: Kadian - Price of Oral Capsules, Extended Release of Dosage 60 mg/24 hr (US$), September’2023
Figure 12-21: Kadian - Price of Oral Capsules, Extended Release of Dosage 70 mg/12 to 24 hr (US$), September’2023
Figure 12-22: Kadian - Price of Oral Capsules, Extended Release of Dosage 80 mg/12 hr, 80 mg/12 to 24 hr and 80 mg/24 hr (US$), September’2023
Figure 12-23: Kadian - Price of Oral Capsules, Extended Release of Dosage 100 mg/12 hr, 100 mg/12 to 24 hr and 100 mg/24 hr (US$), September’2023
Figure 12-24: Kadian - Price of Oral Capsules, Extended Release of Dosage 130 mg/12 to 24 hr and 150 mg/12 to 24 hr (US$), September’2023
Figure 12-25: Kadian - Price of Oral Capsules, Extended Release of Dosage 200 mg/12 to 24 hr and 200 mg/24 hr (US$), September’2023
Figure 12-26: Xtampza ER - Available Dosage Strengths (mg)
Figure 12-27: Xtampza ER - Price of Oral Capsules, Extended Release of Different Doses (US$), September’2023
Figure 12-28: Global - Xtampza ER Annual Sales (US$ Million), 2019-2023*
Figure 12-29: Global - Xtampza ER Quarterly Sales (US$ Million), H1’2023
Figure 12-30: Global - Xtampza ER Quarterly Sales (US$ Million), 2022
Figure 12-31: MS Contin - Available Dosage Strengths (mg)
Figure 12-32: MS Contin - Price of Oral Tablet, Extended Release of Dosage 15 mg/ 8 to 12 hr (US$), September’2023
Figure 12-33: Embeda - Price of Oral Capsules, Extended Release of Different Doses (US$), September’2023
Figure 13-1: Ampyra - Price of Oral Tablet, Extended Release of Dosage 10 mg (US$), September’2023
Figure 13-2: Ampyra/ Fampyra - Global Annual Sales (US$ Million), 2019-2023*
Figure 13-3: Ampyra/ Fampyra - Global Quarterly Sales (US$ Million), H1’2023
Figure 13-4: Ampyra/ Fampyra - Global Quarterly Sales (US$ Million), 2022
Figure 13-5: Tecfidera - Available Dosage Strengths (mg)
Figure 13-6: Tecfidera - Price of Oral Capsule, Delayed Release of Dosage 120 mg (US$), September’2023
Figure 13-7: Global - Tecdifera Annual Sales (US$ Million), 2019-2023*
Figure 13-8: US - Tecdifera Annual Sales (US$ Million), 2019-2023*
Figure 13-9: ROW - Tecdifera Annual Sales (US$ Million), 2019-2023*
Figure 13-10: Global - Tecdifera Quarterly Sales (US$ Million), H1’2023
Figure 13-11: US - Tecdifera Quarterly Sales (US$ Million), H1’2023
Figure 13-12: ROW - Tecdifera Quarterly Sales (US$ Million), H1’2023
Figure 13-13: Global - Tecdifera Quarterly Sales (US$ Million), 2022
Figure 13-14: US - Tecdifera Quarterly Sales (US$ Million), 2022
Figure 13-15: ROW - Tecdifera Quarterly Sales (US$ Million), 2022
Figure 13-16: Rayos - Available Dosage Strengths (mg)
Figure 13-17: Rayos - Price of Oral Tablet, Delayed Release of All Dosages (US$), September’2023
Figure 13-18: US - Rayos Annual Sales (US$ Million), 2019-2023*
Figure 13-19: Global - Rayos Quarterly Sales (US$ Million), H1’2023
Figure 13-20: Global - Rayos Quarterly Sales (US$ Million), 2022
Figure 13-21: Vumerity - Price of Oral Capsule, Delayed Release (US$), September’2023
Figure 13-22: Global - Vumerity Annual Sales (US$ Million), 2019-2023*
Figure 13-23: US - Vumerity Annual Sales (US$ Million), 2019-2023*
Figure 13-24: ROW - Vumerity Annual Sales (US$ Million), 2019-2023*
Figure 13-25: Global - Vumerity Quarterly Sales (US$ Million), H1’2023
Figure 13-26: US - Vumerity Quarterly Sales (US$ Million), H1’2023
Figure 13-27: ROW - Vumerity Quarterly Sales (US$ Million), H1’2023
Figure 13-28: Global - Vumerity Quarterly Sales (US$ Million), 2022
Figure 13-29: US - Vumerity Quarterly Sales (US$ Million), 2022
Figure 13-30: ROW - Vumerity Quarterly Sales (US$ Million), 2022
Figure 13-31: Bafiertam - Price of Oral Capsule, Delayed Release (US$), September’2023
Figure 14-1: Glumetza - Available Dosage Strengths (mg)
Figure 14-2: Glumetza - Price of Oral Tablets, Extended Release of Dosage 500 mg (US$), September’2023
Figure 14-3: Glumetza - Price of Glumetza Oral Tablets, Extended Release of Dosage 1000 mg (US$), September’2023
Figure 14-4: Glucotrol XL - Available Dosage Strengths (mg)
Figure 14-5: Glucotrol XL - Price Oral Tablets Extended Release of Dosage 2.5 mg (US$), September’2023
Figure 14-6: Glucotrol XL - Price of Oral Tablets Extended Release of Dosages 5 mg and 10 mg (US$), September’2023
Figure 14-7: Glucotrol XL - Price of Oral Tablets Extended Release of Dosage 5 mg (US$), September’2023
Figure 14-8: Glucophage XR - Available Dosage Strengths (mg)
Figure 14-9: Glucophage XR - Price of Oral Tablet, Extended Release of Dosage 500 mg (US$), September’2023
Figure 14-10: Glucophage XR - Price of Oral Tablet, Extended Release of Dosage 750 mg (US$), September’2023
Figure 14-11: Bydureon - Price of Powder for Injection of Dosage 2 mg (US$), September’2023
Figure 14-12: Global - Bydureon Annual Sales (US$ Million), 2019-2023
Figure 14-13: US - Bydureon Annual Sales (US$ Million), 2019-2023
Figure 14-14: EU - Bydureon Annual Sales (US$ Million), 2019-2023
Figure 14-15: ROW - Bydureon Annual Sales (US$ Million), 2019-2023
Figure 14-16: Global - Bydureon Quarterly Sales (US$ Million), H1’2023
Figure 14-17: US - Bydureon Quarterly Sales (US$ Million), H1’2023
Figure 14-18: EU - Bydureon Quarterly Sales (US$ Million), H1’2023
Figure 14-19: ROW - Bydureon Quarterly Sales (US$ Million), H1’2023
Figure 14-20: Global - Bydureon Quarterly Sales (US$ Million), 2022
Figure 14-21: US - Bydureon Quarterly Sales (US$ Million), 2022
Figure 14-22: EU - Bydureon Quarterly Sales (US$ Million), 2022
Figure 14-23: ROW - Bydureon Quarterly Sales (US$ Million), 2022
Figure 14-24: Trijardy XR - Price of Oral Tablet, Extended Release of Dosage 10 mg-5 mg-1000 mg and 25 mg-5 mg-1000 mg (US$), September’2023
Figure 14-25: Trijardy XR - Price of Oral Tablet, Extended Release of Dosage 12.5 mg-2.5 mg-1000 mg and 5 mg-2.5 mg-1000 mg (US$), September’2023
Figure 15-1: Procardia XL - Available Dosage Strengths (mg)
Figure 15-2: Procardia XL - Price of Oral Tablet, Extended Release of Dosage 30 mg (US$), September’2023
Figure 15-3: Procardia XL - Price of Oral Tablet, Extended Release of Dosage 60 mg (US$), September’2023
Figure 15-4: Procardia XL - Price of Oral Tablet, Extended Release of Dosage 90 mg (US$), September’2023
Figure 15-5: Toprol XL - Available Dosage Strengths
Figure 15-6: Toprol XL - Price of Oral Tablet, Extended Release of Dosage 25 mg and 50 mg (US$), September’2023
Figure 15-7: Toprol XL - Price of Oral Tablet, Extended Release of Dosage 100 mg (US$), September’2023
Figure 15-8: Toprol XL - Price of Oral Tablet, Extended Release of Dosage 200 mg (US$), September’2023
Figure 15-9: Global - Toprol XL Annual Sales (US$ Million), 2019-2023
Figure 15-10: US - Toprol XL Annual Sales (US$ Million), 2019-2023
Figure 15-11: EU - Toprol XL Annual Sales (US$ Million), 2019-2023
Figure 15-12: ROW - Toprol XL Annual Sales (US$ Million), 2019-2023
Figure 15-13: Global - Toprol XL Quarterly Sales (US$ Million), H1’2023
Figure 15-14: US - Toprol XL Quarterly Sales (US$ Million), H1’2023
Figure 15-15: EU - Toprol XL Quarterly Sales (US$ Million), H1’2023
Figure 15-16: ROW - Toprol XL Quarterly Sales (US$ Million), H1’2023
Figure 15-17: Global - Toprol XL Quarterly Sales (US$ Million), 2022
Figure 15-18: EU - Toprol XL Quarterly Sales (US$ Million), 2022
Figure 15-19: ROW - Toprol XL Quarterly Sales (US$ Million), 2022
Figure 15-20: Adalat CC - Available Dosage Strengths (mg)
Figure 15-21: Adalat CC - Price of Oral Tablet Extended Release of Dosage 30 mg (US$), September’2023
Figure 15-22: Adalat CC - Price of Oral Tablet Extended Release of Dosage 60 mg (US$), September’2023
Figure 15-23: Adalat CC - Price of Oral Tablet Extended Release of Dosage 90 mg (US$), September’2023
Figure 15-24: Verelan PM - Available Dosage Strengths (mg)
Figure 15-25: Verelan PM - Price of Oral Capsule, Extended Release of Dosage 200 mg/24 hr (US$), September’2023
Figure 15-26: Verelan PM - Price of Oral Capsule, Extended Release of Dosage 300 mg/24 hr (US$), September’2023
Figure 15-27: Cardizem LA - Available Dosage Strengths (mg)
Figure 15-28: Cardizem LA - Price of Oral Tablet, Extended Release of Dosage 120 mg/24 hr (US$), September’2023
Figure 15-29: Cardizem LA - Price of Oral Tablet, Extended Release of Dosage 180 mg/24 hr (US$), September’2023
Figure 15-30: Cardizem LA - Price of Oral Tablet, Extended Release of Dosage 240 mg/24 hr (US$), September’2023
Figure 15-31: Cardizem LA - Price of Oral Tablet, Extended Release of Dosage 300 mg/24 hr (US$), September’2023
Figure 15-32: Cardizem LA - Price of Oral Tablet, Extended Release of Dosage 360 mg/24 hr (US$), September’2023
Figure 15-33: Cardizem LA - Price of Oral Tablet, Extended Release of Dosage 420 mg/24 hr (US$), September’2023
Figure 16-1: Zynrelef - Price of Injectable Solution, Extended Release of Different Dosages (US$), September’2023
Figure 16-2: Global - Zynrelef Annual Sales (US$ Million), 2021-2023
Figure 16-3: Global - Zynrelef Quarterly Sales (US$ Million), H1’2023
Figure 16-4: Global - Zynrelef Quarterly Sales (US$ Million), 2022
Figure 17-1: Apretude - Price of Intramuscular Suspension, Extended Release of Different Dosages (US$), September’2023
Figure 17-2: Cabenuva - Price of injectable Suspension, Extended Release of Different Dosages (US$), September’2023
Figure 17-3: Rukobia - Price of injectable Suspension, Extended Release of Different Dosages (US$), September’2023
Figure 18-1: Qelbree - Available Dosage Strengths (mg)
Figure 18-2: Qelbree - Price of Oral Tablet, Extended Release of Dosages 100 mg and 150 mg (US$), September’2023
Figure 18-3: Qelbree - Price of Oral Tablet, Extended Release of Dosage 200 mg (US$), September’2023
Figure 18-4: Global - Qelbree Annual Sales (US$ Million), 2021-2023
Figure 18-5: Global - Qelbree Quarterly Sales (US$ Million), H1’2023
Figure 18-6: Global - Qelbree Quarterly Sales (US$ Million), 2022
Figure 18-7: Jornay PM - Available Dosage Strengths (mg)
Figure 18-8: Jornay PM - Price of Oral Capsule, Extended Release (US$), September’2023
Figure 18-9: Cotempla XR-ODT - Available Dosage Strengths (mg)
Figure 18-10: Cotempla XR-ODT - Price of Oral Capsule, Extended Release (US$), September’2023
Figure 18-11: Adzenys XR-ODT - Available Dosage Strengths (mg)
Figure 18-12: Adzenys XR-ODT - Price of Oral Capsule, Extended Release (US$), September’2023
Figure 18-13: Global - Adzenys XR-ODT and Cotempla XR-ODT Annual Sales (US$ Million), 2021-2023
Figure 18-14: Global - Adzenys XR-ODT and Cotempla XR-ODT Quarterly Sales (US$ Million), H1’2023
Figure 18-15: Global - Adzenys XR-ODT and Cotempla XR-ODTQuarterly Sales (US$ Million), 2022
Figure 19-1: Rinvoq - Available Dosage Strengths (mg)
Figure 19-2: Rinvoq - Price of Oral Capsule, Extended Release of Doses 15 mg and 30 mg (US$), September’2023
Figure 19-3: Rinvoq - Price of Oral Capsule, Extended Release of Doses 45 mg (US$), September’2023
Figure 19-4: Global - Rinvoq Annual Sales (US$ Million), 2019-2023*
Figure 19-5: US - Rinvoq Annual Sales (US$ Million), 2019-2023*
Figure 19-6: ROW - Rinvoq Annual Sales (US$ Million), 2019-2023*
Figure 19-7: Global - Rinvoq Quarterly Sales (US$ Million), H1’2023
Figure 19-8: US - Rinvoq Quarterly Sales (US$ Million), H1’2023
Figure 19-9: ROW - Rinvoq Quarterly Sales (US$ Million), H1’2023
Figure 19-10: Global - Rinvoq Quarterly Sales (US$ Million), 2022
Figure 19-11: US - Rinvoq Quarterly Sales (US$ Million), 2022
Figure 19-12: ROW - Rinvoq Quarterly Sales (US$ Million), 2022
Figure 19-13: Ortikos - Available Dosage Strengths (mg)
Figure 19-14: Ortikos - Price of Oral Capsule, Extended Release (US$), September’2023
Figure 19-15: Xeljanz XR - Available Dosage Strengths (mg)
Figure 19-16: Xeljanz XR - Price of Oral Capsule, Extended Release (US$), September’2023
Figure 19-17: Global - Xeljanz XR Annual Sales (US$ Million), 2019-2023
Figure 19-18: US - Xeljanz XR Annual Sales (US$ Million), 2019-2023
Figure 19-19: EU - Xeljanz XR Annual Sales (US$ Million), 2019-2023
Figure 19-20: ROW - Xeljanz XR Annual Sales (US$ Million), 2019-2023
Figure 19-21: Global - Xeljanz XR Quarterly Sales (US$ Million), H1’2023
Figure 19-22: US - Xeljanz XR Quarterly Sales (US$ Million), H1’2023
Figure 19-23: EU - Xeljanz XR Quarterly Sales (US$ Million), H1’2023
Figure 19-24: ROW - Xeljanz XR Quarterly Sales (US$ Million), H1’2023
Figure 19-25: Global - Xeljanz XR Quarterly Sales (US$ Million), 2022
Figure 19-26: US - Xeljanz XR Quarterly Sales (US$ Million), 2022
Figure 19-27: EU - Xeljanz XR Quarterly Sales (US$ Million), 2022
Figure 19-28: ROW - Xeljanz XR Quarterly Sales (US$ Million), 2022
Figure 20-1: Aemcolo - Price of Oral Capsule, Extended Release (US$), September’2023
Figure 20-2: Talicia - Price of Oral Capsule, Extended Release (US$), September’2023
Figure 21-1: Sublocade - Price of Subcutaneous Solution, Extended Release (US$), September’2023
Figure 21-2: Global - Sublocade Annual Sales (US$ Million), 2019-2023*
Figure 21-3: Global - Sublocade Quarterly Sales (US$ Million), H1’2023
Figure 21-4: Global - Sublocade Quarterly Sales (US$ Million), 2022
Figure 22-1: Astagraf XL - Available Dosage Strengths (mg)
Figure 22-2: Astagraf XL - Price of Oral Capsule, Extended Release (US$), September’2023
Figure 22-3: Envarsus XR - Available Dosage Strengths (mg)
Figure 22-4: Envarsus XR - Price of Oral Capsule, Extended Release of Dosage 0.75 mg (US$), September’2023
Figure 22-5: Envarsus XR - Price of Oral Capsule, Extended Release of Dosage 1 mg (US$), September’2023
Figure 22-6: Envarsus XR - Price of Oral Capsule, Extended Release of Dosage 4 mg (US$), September’2023
Figure 23-1: Accelerative Parameters of Controlled Drug Delivery Systems
Figure 23-2: Major Challenges Faced by Controlled Drug Delivery System
List of Tables
Table 1-1: Major Differences between Conventional and Novel Drug Delivery Systems
Table 1-2: Comparison of Sustained Drug Release and Controlled Drug Release
Table 4-1: US FDA - Some Recently Approved Controlled Release Drugs

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie
  • Antlia Bioscience
  • Arbor Pharmaceuticals (Azurity Pharmaceuticals)
  • AstraZeneca
  • Bausch Health Companies
  • Biodexa Pharmaceuticals
  • Camurus
  • DURECT Corporation
  • Emplicure
  • Endo International
  • HLK Pharmacin
  • Jemincare
  • Johnson & Johnson
  • Luye Pharma Group
  • Lyndra
  • Mallinckrodt plc
  • MedinCell S.A.
  • Merck
  • Otsuka Pharmaceutical
  • Pacira BioSciences
  • Pfizer
  • Purdue Pharma
  • Roche
  • Sanofi
  • Serina Therapeutics
  • Sun Pharmaceutical Industries
  • Supernus Pharmaceuticals
  • Takeda
  • Tris Pharma
  • ViiV Healthcare